Form 8.3 - Horizon Therapeutics plc

LONDON--(BUSINESS WIRE)-- 

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1)	Millennium International Management LP
Company dealt in	Horizon Therapeutics plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	IE00BQPVQZ61
Date of dealing	9^th May 2023

2. INTERESTS AND SHORT POSITIONS

a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	4,788,376 (2.093%)		59 (0.000%)
(2) Derivatives (other than options)	-		-
(3) Options and agreements to purchase/sell	287,600 (0.126%)		1,252,100 (0.547%)
Total	5,075,976 (2.219%)		1,252,159 (0.547%)

b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1. DEALINGS (Note 4)

a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (USD) (Note 5)
Purchase	167	110.76
Purchase	800	110.79
Purchase	401	110.78
Purchase	274	110.77
Purchase	1,100	110.80
Purchase	604	110.67
Purchase	216	111.04
Purchase	1,000	110.65
Purchase	281	110.70
Sale	131	110.70
Purchase	4,104	110.86
Purchase	933	110.81
Purchase	800	110.51
Purchase	813	110.58
Purchase	436	110.66
Purchase	2	110.74
Purchase	123	110.69
Purchase	1,377	110.57
Purchase	36	110.75
Purchase	2,007	110.52
Purchase	150	110.64
Purchase	775	110.50
Purchase	100	110.49
Purchase	612	110.56
Purchase	808	110.60
Purchase	9,523	111.00
Purchase	2,301	110.99
Purchase	100	110.97
Purchase	1,510	110.88
Purchase	800	110.63
Purchase	103	110.59
Purchase	500	110.98
Purchase	900	110.85
Purchase	34	111.02
Purchase	1,200	110.91
Purchase	300	110.82
Purchase	848	110.89
Purchase	5,837	110.87
Purchase	1,141	110.95
Purchase	300	110.94
Purchase	3,925	110.90
Purchase	1,728	110.83
Purchase	700	110.92
Purchase	789	110.84
Purchase	475	110.96
Purchase	12	110.55
Purchase	1	111.04
Purchase	24	110.65
Purchase	35	110.57
Purchase	24	110.72
Purchase	12	110.75
Sale	2	110.88
Purchase	166	110.98
Purchase	12	111.01
Sale	72	111.01
Purchase	6	110.85
Purchase	31	111.02
Sale	15	111.02
Purchase	11	111.03
Sale	15	111.03
Sale	31	110.91
Sale	26	110.89
Purchase	87	110.87
Sale	18	110.90
Purchase	12	110.47
Purchase	6	110.84
Purchase	1	110.96
Purchase	18	111.13
Sale	500	110.76
Sale	2,296	110.79
Sale	500	110.78
Sale	756	110.77
Sale	209	110.80
Sale	9	110.67
Sale	1,888	111.04
Purchase	1,838	110.65
Sale	650	110.65
Sale	591	110.70
Sale	409	110.86
Sale	400	110.81
Purchase	100	110.51
Sale	6	110.51
Purchase	2,500	110.69
Sale	3,400	110.69
Purchase	1,302	110.57
Sale	35	110.57
Sale	199	110.72
Sale	5,000	110.75
Purchase	5,825	110.52
Sale	45	110.52
Sale	2,845	110.64
Purchase	560	110.50
Sale	2,000	110.71
Sale	47	110.56
Sale	10	110.60
Sale	9,342	111.00
Sale	28	110.97
Purchase	543	110.88
Sale	530	110.88
Sale	1,300	110.63
Sale	4,617	110.98
Sale	1,031	111.01
Purchase	6	110.62
Sale	5,300	110.62
Purchase	100	110.85
Sale	1,294	110.85
Purchase	1,800	111.02
Sale	3,754	111.02
Sale	1,100	111.03
Sale	278	110.91
Sale	1,000	111.10
Sale	2,624	111.17
Sale	1,175	111.18
Sale	1,200	111.23
Sale	2,230	110.73
Sale	25	110.82
Purchase	286	110.89
Purchase	1,473	110.87
Sale	247	110.87
Sale	40	110.94
Sale	10,011	110.90
Sale	220	110.83
Purchase	151	110.84
Sale	332	110.96
Sale	300	111.14
Sale	80	111.15
Sale	200	111.08
Purchase	4,000	110.53
Sale	1,000	111.25
Sale	200	111.20
Sale	105	110.61
Sale	199	110.55
Sale	59	111.04

b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD

Nature of transaction (Note 6)

Number of relevant securities (Note 7)

Price per unit (USD) (Note 5)

c) Options transactions in respect of existing relevant securities

i) Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price (USD)	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)
Put Option	Selling	31,500	100.00	American	5/19/2023

ii) Exercising

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 5)

d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)

Details

Price per unit (if applicable) (Note 5)

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None.

Is a Supplemental Form 8 attached? (Note 9) YES

Date of disclosure	10^th May 2023
Contact name	Sirina Kumar
Telephone number	[phone]
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

Ap32

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND

RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2022

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING

OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND

RIGHTS TO SUBSCRIBE FOR NEW SECURITIES

1. KEY INFORMATION

Full name of person making disclosure:	Millennium International Management LP
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:	Horizon Therapeutics plc

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of relevant security	Product description e.g. call option	Written or purchased	Number of securities to which option or derivative relates	Exercise price per unit (USD)	Type e.g. American, European etc.	Expiry date
IE00BQPVQZ61	Put Option	Purchased	1,100	90.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	11,500	110.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Written	262,400	115.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	42,500	120.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	35,400	110.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	2,900	80.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	300	80.00	American	1/17/2025
IE00BQPVQZ61	Put Option	Purchased	300	90.00	American	1/19/2024
IE00BQPVQZ61	Call Option	Purchased	1,200	110.00	American	8/18/2023
IE00BQPVQZ61	Call Option	Written	201,200	115.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Written	221,000	80.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Purchased	223,500	100.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	3,600	105.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	10,900	105.00	American	7/21/2023
IE00BQPVQZ61	Call Option	Written	100,000	115.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	46,600	85.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	155,000	100.00	American	6/16/2023
IE00BQPVQZ61	Call Option	Purchased	300	110.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	300	110.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	200,000	100.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Purchased	3,500	95.00	American	6/16/2023
IE00BQPVQZ61	Call Option	Written	300	110.00	American	7/21/2023
IE00BQPVQZ61	Put Option	Written	300	110.00	American	7/21/2023
IE00BQPVQZ61	Call Option	Written	400	100.00	American	5/12/2023
IE00BQPVQZ61	Call Option	Written	400	101.00	American	5/12/2023
IE00BQPVQZ61	Call Option	Written	400	102.00	American	5/12/2023
IE00BQPVQZ61	Call Option	Written	400	103.00	American	5/12/2023
IE00BQPVQZ61	Call Option	Written	400	104.00	American	5/12/2023
IE00BQPVQZ61	Call Option	Written	400	105.00	American	5/12/2023
IE00BQPVQZ61	Call Option	Written	400	106.00	American	5/12/2023
IE00BQPVQZ61	Call Option	Written	400	107.00	American	5/12/2023
IE00BQPVQZ61	Call Option	Written	400	108.00	American	5/12/2023
IE00BQPVQZ61	Call Option	Written	400	109.00	American	5/12/2023
IE00BQPVQZ61	Call Option	Written	400	110.00	American	5/12/2023
IE00BQPVQZ61	Call Option	Written	400	111.00	American	5/12/2023
IE00BQPVQZ61	Put Option	Written	600	100.00	American	5/12/2023
IE00BQPVQZ61	Put Option	Written	800	101.00	American	5/12/2023
IE00BQPVQZ61	Put Option	Written	700	102.00	American	5/12/2023
IE00BQPVQZ61	Put Option	Written	700	103.00	American	5/12/2023
IE00BQPVQZ61	Put Option	Written	1,000	104.00	American	5/12/2023
IE00BQPVQZ61	Put Option	Written	1,000	105.00	American	5/12/2023
IE00BQPVQZ61	Put Option	Written	1,000	106.00	American	5/12/2023
IE00BQPVQZ61	Put Option	Written	1,000	107.00	American	5/12/2023
IE00BQPVQZ61	Put Option	Written	1,000	108.00	American	5/12/2023
IE00BQPVQZ61	Put Option	Written	1,000	109.00	American	5/12/2023
IE00BQPVQZ61	Put Option	Written	1,000	110.00	American	5/12/2023
IE00BQPVQZ61	Put Option	Written	1,000	111.00	American	5/12/2023

3. AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

Ap33

4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS’ AND OTHER EMPLOYEE OPTIONS)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Category Code: RET

Sequence Number: 1094027

Time of Receipt (offset from UTC): 20230510T134611+0100